Mineralys Therapeutics, Inc. MLYS Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCash.
The source filing: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 5:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001933414-26-000084
All highly liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. The Company’s cash and cash equivalents balances as of March 31, 2026 and December 31, 2025 include cash balances and amounts held primarily in interest-bearing money market accounts and U.S. Treasury bills. As of March 31, 2026 and December 31, 2025, the Company did not have any restricted cash balances. The following table provides a reconciliation of cash and cash equivalents as reported in the condensed statements of cash flows to the condensed balance sheets (in thousands):
Item 1. Financial Statements
FAQ
- What is Mineralys Therapeutics, Inc.'s restricted cash?
- Mineralys Therapeutics, Inc. (MLYS) reported restricted cash of $0 in Q1 2026.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s restricted cash?
- Over 4 years (2021 to 2025), Mineralys Therapeutics, Inc.'s restricted cash has grown at a -100.0% compound annual growth rate (CAGR), from $50K to $0.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Mineralys Therapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
